Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Palovarotene - Clementia Pharmaceuticals

Next Previous
Drug Profile

Palovarotene - Clementia Pharmaceuticals

Alternative Names: Clm-001; IPN-60120; R-667; RAR-gamma; RG-667; RO-3300074; Sohonos

Latest Information Update: 14 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Clementia Pharmaceuticals; Ipsen; Roche
  • Class Benzoic acids; Eye disorder therapies; Naphthalenes; Pyrazoles; Small molecules
  • Mechanism of Action Retinoic acid receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fibrodysplasia ossificans progressiva
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fibrodysplasia ossificans progressiva
  • Discontinued Bone disorders; Dry eyes; Emphysema

Most Recent Events

  • 14 Mar 2025 Ipsen initiates a phase I pharmacokinetic trial in USA (PO) (NCT06908954)
  • 30 Nov 2024 Ipsen completes the phase III PIVOINE trial in Fibrodysplasia ossificans progressiva (In adolescents, In adults) in Argentina, Australia, Brazil, Canada, France, Italy, Spain, Sweden, UK, and the US (NCT05027802),
  • 08 Feb 2024 Launched for Fibrodysplasia ossificans progressiva (In adolescents, In children, In adults) in USA (PO), before February 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top